SCHEMBL25201620

SCHEMBL25201620

COC(=O)c1sc(Br)cc1S(N)(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.45
CA1 P00915 3/20 0.45
CA9 Q16790 3/20 0.45
CA5A P35218 2/20 0.45
GSK3B P49841 1/20 0.41
KDM4E B2RXH2 4/20 0.40
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
ALDH1A1 P00352 3/20 0.37
LMNA P02545 2/20 0.37
CA12 O43570 2/20 0.37
CA14 Q9ULX7 2/20 0.37
HTT P42858 1/20 0.37
OPRD1 P41143 1/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25202684 0.85 VCAM1 (0.39) GSK3BKDM4EKMT2AMAPTHSD17B10
SCHEMBL25202606 0.84 MAPT (0.38) GSK3BKDM4EKMT2AMAPTHSD17B10
SCHEMBL319034 0.83 GSK3B (0.53) CA2CA1CA9GSK3BKDM4E
SCHEMBL25207145 0.80 CA1 (0.49) CA2CA1CA9CA5AGSK3B
SCHEMBL1374020 0.78 TSHR (0.44) CA2CA1CA9GSK3BKDM4E
SCHEMBL102283 0.76 KDM4E (0.53) KDM4EKMT2AMAPTHSD17B10TSHR
SCHEMBL4363783 0.75 MAPT (0.58) CA2CA1CA9CA5AKDM4E
SCHEMBL2730725 0.74 MAPT (0.44) GSK3BKDM4EKMT2AMAPTHSD17B10
SCHEMBL1971697 0.74 MAPT (0.44) CA2CA1CA9GSK3BKDM4E
SCHEMBL21962947 0.73 PTGS1 (0.45) CA2CA1CA9CA5AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 WO disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 CA2 4760/4885CA1 4865/4885CA9 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.